Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Akamai
AKAM
$17.9B
| $11.1M | 0.01% |
128,800
+95,700
| +289% | +$8.37M |
|
|
CHMI
1377
Cherry Hill Mortgage Investment Corp
CHMI
$108M
| $11.1M | 0.01% |
762,058
+113,800
| +18% | +$1.59M |
|
|
BELFB
1378
Bel Fuse Inc Class B
BELFB
$4.17B
| $11.1M | 0.01% |
541,823
+35,000
| +7% | +$575K |
|
1379
BancFirst
BANF
$3.89B
| $11.1M | 0.01% |
177,300
-62,224
| -26% | -$3.66M |
|
1380
American Airlines Group
AAL
$9.86B
| $11.1M | 0.01% |
+385,832
| New | +$11M |
|
1381
Novanta
NOVT
$6.29B
| $11.1M | 0.01% |
125,000
-122,200
| -49% | -$10.5M |
|
1382
e.l.f. Beauty
ELF
$5.5B
| $11M | 0.01% |
684,100
+260,700
| +62% | +$4.34M |
|
1383
Culp Inc
CULP
$43.7M
| $11M | 0.01% |
809,257
+48,557
| +6% | +$745K |
|
1384
Star Group
SGU
$410M
| $11M | 0.01% |
1,164,316
+88,400
| +8% | +$830K |
|
|
RVNC
1385
DELISTED
Revance Therapeutics, Inc.
RVNC
| $11M | 0.01% |
677,473
-198,900
| -23% | -$3.08M |
|
1386
Citi Trends
CTRN
$610M
| $11M | 0.01% |
474,625
+2,335
| +0.5% | +$45.5K |
|
1387
Clarus
CLAR
$140M
| $11M | 0.01% |
811,532
-105,172
| -11% | -$1.3M |
|
1388
AutoNation
AN
$6.9B
| $10.9M | 0.01% |
225,100
-130,500
| -37% | -$6.61M |
|
1389
St. Joe Company
JOE
$3.87B
| $10.9M | 0.01% |
549,500
-105,571
| -16% | -$1.96M |
|
1390
RPC Inc
RES
$1.42B
| $10.9M | 0.01% |
2,078,549
-811,154
| -28% | -$3.64M |
|
|
RWT
1391
Redwood Trust
RWT
$603M
| $10.9M | 0.01% |
656,700
-194,000
| -23% | -$3.19M |
|
1392
Enpro
NPO
$7.21B
| $10.8M | 0.01% |
161,804
+54,504
| +51% | +$3.62M |
|
1393
BlackLine
BL
$1.77B
| $10.8M | 0.01% |
209,700
+83,800
| +67% | +$4.18M |
|
|
AMWD
1394
DELISTED
American Woodmark
AMWD
| $10.8M | 0.01% |
103,300
+80,399
| +351% | +$8.08M |
|
1395
Dorian LPG
LPG
$2B
| $10.8M | 0.01% |
696,820
-27,641
| -4% | -$364K |
|
1396
Primis Financial Corp
FRST
$413M
| $10.8M | 0.01% |
659,713
+70,200
| +12% | +$1.11M |
|
|
PTVCB
1397
DELISTED
Protective Insurance Corporation Class B Common Stock
PTVCB
| $10.8M | 0.01% |
669,977
+7,700
| +1% | +$125K |
|
1398
Brookfield Infrastructure Partners
BIP
$18.3B
| $10.8M | 0.01% |
+361,536
| New | +$10.8M |
|
1399
CNB Financial Corp
CCNE
$1.04B
| $10.8M | 0.01% |
329,102
+6,700
| +2% | +$209K |
|
|
ARA
1400
DELISTED
American Renal Associates Holdings, Inc
ARA
| $10.8M | 0.01% |
1,036,700
+91,725
| +10% | +$784K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.